Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
Portfolio Pulse from Charles Gross
Vivos Therapeutics, Inc. announced that its CARE oral medical devices for treating sleep related breathing disorders, including obstructive sleep apnea, have received full approval for Medicare reimbursement. This approval enables Medicare beneficiaries to receive coverage and reimbursement for the devices, effective immediately.
April 09, 2024 | 9:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivos Therapeutics' CARE oral medical devices have been fully approved for Medicare reimbursement, potentially increasing accessibility for millions of Medicare beneficiaries and possibly boosting the company's revenues.
The full approval for Medicare reimbursement of Vivos Therapeutics' CARE oral medical devices is a significant milestone. It not only enhances the product's accessibility to a broader audience of Medicare beneficiaries but also has the potential to significantly increase the company's revenues. Given the size of the Medicare market and the prevalence of sleep-related breathing disorders, this approval could lead to increased demand for the CARE devices, positively impacting VVOS's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100